Checkpoint Immunotherapy Response Described in Tumors with Gene Fusion-Based Neoantigens

NEW YORK (GenomeWeb) – A team from Memorial Sloan Kettering Cancer Center (MSKCC) and the University of Gothenburg have demonstrated that new antigens formed from gene fusion events can prompt a T cell immune response against head and neck cancers and other tumor types, raising the possibility of using checkpoint blockade immunotherapy to treat some fusion-positive tumors.